Literature DB >> 17538000

Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients.

Edwin DeJesus1, Barry M Rodwick, Daniel Bowers, Calvin J Cohen, Daniel Pearce.   

Abstract

OBJECTIVE: To determine whether dronabinol affects appetite and weight status in patients living with HIV/AIDS.
METHODS: A retrospective chart review was conducted to analyze weight and appetite changes and nausea status in patients with HIV/AIDS who received dronabinol for 3 to 12 months from January 11, 1993, to March 17, 2003.
RESULTS: Of the 117 patients who lost weight before baseline, 63% maintained or gained weight. In patients receiving dronabinol for 1 year, the mean weight gain (+/- SD) was 3.7 +/- 10.6 lb. The percentage of patients experiencing loss of appetite decreased significantly from 71% at baseline to 26% at 1 month (P < .001) and continued to decline throughout the trial. The percentage of patients experiencing nausea at baseline (38%) decreased consistently from week 2 on; this change from baseline was significant at month 6 (P = .031).
CONCLUSION: When taken for 3 months to 1 year, dronabinol significantly improves appetite and reverses weight loss in patients living with HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538000     DOI: 10.1177/1545109707300157

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  11 in total

1.  Chronic Δ⁹-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques.

Authors:  Angela M Amedee; Whitney A Nichols; Nicole J LeCapitaine; Curtis Vande Stouwe; Leslie L Birke; Nedra Lacour; Peter J Winsauer; Patricia E Molina
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

2.  Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.

Authors:  Edward J Hoffenberg; Heike Newman; Colm Collins; Sally Tarbell; Kristina Leinwand
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 3.  Macronutrient supplementation and food prices in HIV treatment.

Authors:  Kevin A Sztam; Wafaie W Fawzi; Christopher Duggan
Journal:  J Nutr       Date:  2009-11-25       Impact factor: 4.798

Review 4.  Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Authors:  Slava Rom; Yuri Persidsky
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-08       Impact factor: 4.147

Review 5.  What we know and do not know about the cannabinoid receptor 2 (CB2).

Authors:  Anna Maria Malfitano; Sreemanti Basu; Katarzyna Maresz; Maurizio Bifulco; Bonnie N Dittel
Journal:  Semin Immunol       Date:  2014-05-28       Impact factor: 11.130

Review 6.  Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week.

Authors:  Ersilia M DeFilippis; Navkaranbir S Bajaj; Amitoj Singh; Rhynn Malloy; Michael M Givertz; Ron Blankstein; Deepak L Bhatt; Muthiah Vaduganathan
Journal:  J Am Coll Cardiol       Date:  2020-01-28       Impact factor: 24.094

Review 7.  Mini-review: The therapeutic role of cannabinoids in neuroHIV.

Authors:  Barkha J Yadav-Samudrala; Sylvia Fitting
Journal:  Neurosci Lett       Date:  2021-02-12       Impact factor: 3.046

8.  Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Authors:  Chaela Presley; Ammaar Abidi; Satyendra Suryawanshi; Suni Mustafa; Bernd Meibohm; Bob M Moore
Journal:  Pharmacol Res Perspect       Date:  2015-07-06

Review 9.  Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS.

Authors:  Melissa E Badowski; Sarah E Perez
Journal:  HIV AIDS (Auckl)       Date:  2016-02-10

Review 10.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.